Sector News

GSK appoints Debjit Rudra as South-east Asia GM

September 3, 2015
Life sciences

GlaxoSmithKline (GSK) Consumer Healthcare has appointed Debjit Rudra as General Manager of its south-east Asia operations.

Based in Singapore, Mr Debjit will oversee GSK’s consumer healthcare business across South East Asia, reporting directly to Zubair Ahmed who heads the Asia Middle East Africa region.

He was previously Asia Vice President of Unilever’s Household Care division. He held key positions in sales, marketing and senior regional leadership roles during his 22-year tenure at the company.

Most recently, Mr Debjit assumed the role of Asia Vice President of Unilever’s Household Care division, playing a central role in the development and implementation of Unilever’s strategic roadmap for the category across Asia and ANZ.

Source: Asia Online

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”